Compounds > canertinib
Page last updated: 2024-09-04

canertinib and gsk 1363089

canertinib has been researched along with gsk 1363089 in 3 studies

Compound Research Comparison

Studies
(canertinib)		Trials
(canertinib)		Recent Studies (post-2010)
(canertinib)		Studies
(gsk 1363089)		Trials
(gsk 1363089)		Recent Studies (post-2010) (gsk 1363089)
1249651319124

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)gsk 1363089 (IC50)
Epidermal growth factor receptorHomo sapiens (human)1.5147
High affinity nerve growth factor receptorHomo sapiens (human)0.003
Acyl-CoA desaturase 1Rattus norvegicus (Norway rat)0.0004
Hepatocyte growth factor receptorHomo sapiens (human)0.056
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)0.01
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0098
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1814
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.2346
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.2541
Ephrin type-A receptor 2Homo sapiens (human)0.0019
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.0417
Delta-type opioid receptorMus musculus (house mouse)0.0049
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.003
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1234
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.1806
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)2.99
Mu-type opioid receptorMus musculus (house mouse)0.0056
4-aminobutyrate aminotransferase, mitochondrialMus musculus (house mouse)0.0086
Angiopoietin-1 receptorHomo sapiens (human)0.0011
Macrophage-stimulating protein receptorHomo sapiens (human)0.1798
Homeodomain-interacting protein kinase 1Homo sapiens (human)0.1
Cyclin-dependent kinase-like 3Homo sapiens (human)7.9
Homeodomain-interacting protein kinase 4Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 2Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 3Homo sapiens (human)0.1
ALK tyrosine kinase receptorHomo sapiens (human)3.18

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

3 other study(ies) available for canertinib and gsk 1363089

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017